Ovarian cancer survival in Australia, Canada, Denmark, Norway and the United Kingdom (1995-2007): The International Cancer Benchmarking Partnership
United Kingdom 
You need to have a Flash player to see the MULTIWEBCAST Viewer. Please click on the link below to download Flash Player.
Get Flash Player
12 slide(s) – English – 2011-09-11
Introduction:
Cancer survival is a key measure of the effectiveness of health-care systems and international differences in survival represent many avoidable deaths. EUROCARE-4 (1995-99) reported lower ovarian survival in the UK and Denmark compared to the best performing countries in Europe. Module 1 of the International Cancer Benchmarking Partnership examines cancer survival in four cancers.
Aims:
To examine ovarian cancer relative survival from 1995 to 2007 in five countries with population-based cancer registration and broadly similar healthcare systems and spending - Australia, Canada, Denmark, Norway and the United Kingdom.
Methods:
Data from population-based cancer registries in 11 jurisdictions in five countries were provided for 137,199 adults diagnosed with primary ovarian cancer during 1995-2007. 121,059 women (15-99 years) were eligble for analysis. Data quality control and analyses were done centrally with a common protocol. 1-year and 5-year age standardised relative survival were estimated after constructing complete life tables to control for background mortality by single age and calendar year.
Results:
Survival trends show improvements but persistent differences in ovarian cancer survival between countries. As with the other cancer sites studied (Breast, Colorectal and Lung), ovarian cancer survival was highest in Australia, Canada and Norway and lowest in Denmark and the United Kingdom. These survival differences arose mainly during the first year after diagnosis and were more marked for women aged 65 or older at diagnosis.
Conclusions:
The survival patterns are consistent with later diagnosis or differences in treatment, particularly in Denmark and the UK, and in patients aged 65 or over. Further studies will examine the influence of treatment and stage on survival.
|
